{"database": "lobbying", "table": "lobbying_activities", "rows": [[2685033, "d1c2b6be-38ca-4cf5-813e-0fb1763e8153", "Q3", "AMERICAN SOCIETY OF ADDICTION MEDICINE", 401104864, "AMERICAN SOCIETY OF ADDICTION MEDICINE", 2021, "third_quarter", "INS", "Advocated for Increased appropriations for HRSAs Substance Use Disorder Treatment and Recovery Loan Repayment Program. This program provides student loan repayment for addiction treatment professionals who commit to working in underserved or high-risk communities. \n\nAdvocated for increased appropriations for HRSAs Addiction Medicine Fellowship Program. This\nProgram provides grants to institutions with training opportunities for fellows in addiction medicine and addiction psychiatry who have demonstrated interest in providing addiction treatment in underserved communities\n\nAdvocated for increased appropriations for HRSAs Integrated Substance Use Disorder\nTraining Program. This program provides grants to expand the number of nurse practitioners, physician assistants, psychologists, and social workers trained to provide addiction and mental health services in underserved community-based settings that integrate primary care, mental health, and addiction services. \n\nAdvocated for increased appropriations for federal initiatives that lead to a more diverse addiction treatment workforce, such as scholarships and loan repayment targeting\nunderrepresented minority addiction medicine professionals, including SAMHSAs\nMinority Fellowship Program.\n\nAdvocated for the alignment of coverage and payment policies in Medicare and Medicaid with evidence-based and nationally recognized addiction treatment and placement criteria and\nstandards (e.g., The ASAM Criteria). This would include permanent modification to the Institutions for Mental Diseases (IMD) exclusion to allow federal Medicaid funds to serve individuals with SUDs in those residential and inpatient settings that are able to demonstrate that patient assessments, clinical services, level-of-care and length-of-stay recommendations are consistent with The ASAM Criteria and that evidence based medication management using Food and Drug Administration (FDA)-approved medications are available to patients in such settings\n\nAdvocated for regulatory/sub-regulatory/application guidance that would require the use of evidence-based practices in the Substance Abuse Prevention and Treatment (SAPT) Block Grant,\nincluding requiring each grantee delivering SUD treatment services to provide access to\nall FDA-approved medications for SUDs treated by that grantee. Advocated for a requirement that SAPT, State Opioid Response Grant (SOR), and Rural Communities Opioid Response Program grantees that receive grant funds for the delivery of addiction treatment services should be limited to Medicaid providers in order to better integrate federal grant dollars and\nMedicaid funds and Administration support for increased oversight and improved mechanisms for ensuring that such funding does not supplant the consistent and scalable funding that Medicaid (or Medicare) provides.\n\nAdvocated for S 2235/HR 2067 - Medication Access and Training Expansion (MATE) Act of 2021: This legislation would ensure most Drug Enforcement Agency (DEA) controlled medication\nprescribers have a baseline knowledge of how to identify, treat, and manage patients\nwith SUD and would allow accredited health professional schools and residency\nprograms to fulfill the training requirement through their own curricula, as well as provide\nthem with resources to do so.   Advocated for simultaneous passage of S 445/HR 1384 - Mainstreaming Addiction Treatment (MAT) Act, which would eliminate the requirement that practitioners apply for a separate waiver through the DEA to prescribe buprenorphine for addiction and eliminate the patient limits on buprenorphine prescribers.\n\nAdvocated for S 285/HR 955 - the Medicaid Reentry Act: This legislation would allow for reestablishment of health insurance coverage under Medicaid for eligible individuals who\nare incarcerated, during the 30-day period preceding their release from jail or prison. \n\nAdvocated for S 1821/HR 3514 - the Humane Correctional Health Care Act, which\nwould repeal the inmate exclusion that bars the use of federal Medicaid matching funds\nfrom covering health care services in jails and prisons.\n\nAdvocated for S1727/HR 3450 - The Medicaid Bump Act of 2021: This legislation would provide an enhanced Medicaid Federal Medical Assistance Percentage rate of 90 percent for State Medicaid spending on mental health and substance use disorder services in excess of\n2019 levels. It would also require states to use the additional federal funds as a supplement to rather than a replacement for state funding levels, and to use the funds to increase the capacity, efficiency, and quality of behavioral health services, including through increasing provider reimbursement rates;\n\nAdvocated for Section 9 of S. 1010 - the Turn the Tide Act - These provisions would increase Medicaid fees for addiction treatment services to at least Medicare levels;\n\nAdvocated for HR 1364 - the Parity Enforcement Act: This legislation would expand the U.S. Department of Labors authority to hold health insurers and plan sponsors accountable for offering health plans that violate the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 or for employing utilization review processes that prove more restrictive for mental\nhealth and addiction care than for other medical care in violation of the MHPAEA\n\nAdvocated for S 340/HR 1674 - TREATS Act: This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Acts in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth. It would also clarify Medicares\ncontinued ability, beyond the COVID-19 public health emergency, to reimburse for \naudio-only, SUD and mental health telehealth services after an in-person or telehealth\nevaluation.  Provided technical assistance regarding a possible audio-only exception to Ryan Haight for initiation of buprenorphine for OUD.\n\nAdvocated for HR 3925 Reducing Barriers to Substance Use Treatment Act: This legislation would prohibit states receiving Federal funding for medication-assisted treatment under Medicaid from imposing utilization control policies or procedures (as defined by the Secretary of\nthe Department of Health and Human Services), including prior authorization\nrequirements, with respect to such treatment.\n\nAdvocated for the Administration to support continuous collaboration and sharing of information between the Centers for Medicare & Medicaid Services (CMS) and SAMHSA, which should include new, strategic efforts to provide technical assistance funds to states to support their operation of CMS-approved Section 1115 SUD waivers related to the IMD exclusion and to enhance their care delivery systems for patients. \n\nAdvocated for the Administration to increase promotion to State Medicaid programs of adoption of two, new sets of bundled G codes to increase or establish payment for outpatient opioid use disorder (OUD) treatment and treatment services provided by opioid treatment programs (OTPs)\nat Medicare payment rates or higher. \n\nAdvocated for the Administration to support the following regulatory and administrative efforts that would reduce barriers to accessing addiction treatment:\n\n Creation of safe-harbor provisions to the Anti-Kickback Statute and Eliminating\nKickbacks in Recovery Act Civil, as they may be applied to the implementation of\ncontingency management (CM) for the treatment of addiction. \n\n Approval of a prescription to over the counter (OTC) switch for at least one naloxone\nproduct. This change would save lives and reduce existing barriers that prevent access to\nthis critical medication;\n\n Regulatory changes that would allow Medicaid reimbursement for the room and board\nportion of SUD residential levels of care that meet level of care standards set forth in The\nASAM Criteria;\n\n Regulatory (or legislative) changes that would create a special registration exemption \nfor jails, prisons, and their authorized personnel to prescribe and otherwise dispense\ncontrolled medications for initiation, maintenance or withdrawal management of OUD\nthat is significantly less burdensome than currently applicable registration requirements\nin the Controlled Substances Act and related regulations. Such special registration should \nnot limit the number of persons who are detained or incarcerated who can be treated\nwith such medications by a qualified practitioner;\n\n Regulatory (or legislative) changes that would allow pharmacy dispensing and/or\nadministration of methadone that has been prescribed by a legally authorized prescriber\nof controlled medications who is affiliated with an OTP or is a board-certified addiction\nspecialist physician;\n\n Regulatory (or legislative) changes that would make permanent the opioid treatment\nprogram (OTP) flexibilities, including the methadone unsupervised dosing flexibilities,\nimplemented during the COVID-19 Public Health Emergency while continuing study of\nthe impact of these flexibilities;\n\n Assessment of current opioid order systems and monitoring programs to more fully\nunderstand the potential negative implications for patient access to buprenorphine at\npharmacies and other controlled substance medications used to treat OUD;\n;\n\n In the absence of Congressional action to eliminate the x-waiver, efforts to increase the\nDATA 2000 waiver patient limit -- aka, the applicable number;\n\n Issuance of regulations relating to a special registration for telemedicine, as was \ndirected in Section 3232 of the SUPPORT Act of 2018. \n\n\nAdvocated for the S.834/H.R.2256 Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years, including its inclusion in the next reconciliation package\n\nAdvocated for House Resolution 349, which would support the goals of Overdose Awareness Day by lowering the United States flag to halfstaff on all Federal buildings on August 31st of each year.\n\nAdvocated for the Support, Treatment, and Overdose Prevention of (S.T.O.P) Fentanyl Act of 2021 (H.R. 2366 / S. 1457). This legislation would expand fentanyl research and education, enhance overdose prevention and access to substance use disorder (SUD) treatment, and provide critical public health data and additional training support for various stakeholders. \n\nAdvocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as \"time in treatment\" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of prescribers\n\nSubmitted a comment letter to the Centers for Medicare & Medicaid Services (CMS) outlining suggested improvements to the proposed Physician Payment Schedule for calendar year (CY) 2022. Among other recommendations, ASAM urged that CMS work with Congress to avoid a 2.5% cut in reimbursements for addiction medicine (ADM), finalize coding and payment rules for take-home naloxone nasal spray, and extend audio-only flexibility for opioid treatment programs (OTPs) to furnish therapy and counseling payments for substance use disorder (SUD). \n\nAdvocated for the inclusion of enhanced mental health and substance use disorder (SUD) parity enforcement within the Senates version of the budget reconciliation proposal. These enhanced enforcement measures would authorize the Department of Labor to assess civil monetary penalties against insurers that violate the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008.  Supported $195 million over five years to the Employee Benefits Security Administration for enforcement.\n\n Advocated for the Moms Matter Act (H.R. 909). The Moms Matter Act is a bipartisan bill that would increase federal funding for culturally congruent, community-based mental and behavior health programs.\n\nAdvocated for H.R 1693 / S. 79, the Eliminating a Quantifiably Unjust Application of the Law Act. This legislation would eliminate the federal crack and powder cocaine sentencing disparity and apply it retroactively to those already convicted or sentenced. \n\nSupported nomination of Dr. Rahul Gupta to lead the Office of National Drug Control Policy (ONDCP), a critical position for coordinating the nations drug policy and response to the nations drug addiction and overdose crisis. \n\n\nSupported the Excellence in Mental Health and Addiction Treatment Expansion Act (S. 2069/H.R. 4323). This legislation would allow for every state and territory the ability to join the Certified Community Behavioral Health Clinic (CCBHC) demonstration and would authorize investments in the model for current and prospective CCBHCs.\n\nSupported implemented recommendations regarding the CARES Acts amendment of 42 CFR Part 2 to advance further alignment of 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO).\n\n\nAdvocated for H.R. 2786/ S. 1314, the Tobacco Tax Equity Act of 2021, which would increase the federal excise tax on cigarettes and set federal tax rates for other tobacco products at an equivalent level. \n\nSupported the tobacco tax provisions included in the portion of the Build Back Better Act that was approved by the Ways and Means Committee\n\nAdvocated for passage of the Advancing FASD Research, Services, and Prevention Act (S.2238 and H.R.4151), known as the FASD Respect Act. The legislation would in part reauthorize and strengthen existing federal FASD programs at NIAAA, CDC, and HRSA, and for the first time calls for long-neglected, meaningful support for individuals and families living with FASD.\n\nSupported H.R.4244 - STOP Stigma Act, which would make amendments to the names of certain agencies to help end the stigmatization of substance use disorder, and for other purposes.\n\nSupported the National Committee on Vital and Health Statistics (NCVHS) efforts to enhance the exchange of clinical and administrative data through their recommendations to the Secretary but highlighted the important role of the Current Procedural Terminology (CPT) code set as  serving the needs of a data-driven health system by allowing physicians, patients, researchers, medical groups, allied health care professionals, health systems, hospitals, medical coders, accreditation organizations, payers, and health information technology professionals to easily exchange data on the medical services and procedures provided to patients.\n\n\nSupported draft legislation that would amend the Controlled Substances Act to increase the number of days before which certain controlled substances for maintenance or detoxification treatment must be administered, and for other purposes.", "Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)", null, 70000, 0, 0, "2021-10-18T13:28:40.217000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2685033"], "units": {}, "query_ms": 1.2257570633664727, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}